Details:
Microba’s Cancer Immuno-Oncology Neoadjuvant Therapy is targeting discovery and development of a microbiome therapy to improve response rates in cancer patients receiving immune checkpoint inhibitor (ICI) therapy, with a specific focus on Melanoma and Lung cancer patients.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Garvan Institute of Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
The project, commencing in March will help BioCina address the post-pandemic mRNA demand for specific and essential attributes of new RNA products. It's anticipated the market will prioritize sophisticated LNP (lipid nanoparticle) formulations.
Lead Product(s): RNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Vaccine
Partner/Sponsor/Collaborator: Australian Government Department of Industry
Deal Size: $8.3 million Upfront Cash: Undisclosed
Deal Type: Funding April 05, 2022
Details:
Collaboration will leverage Onko-Innate’s deep expertise in NK Cell Tumor Biology to discover novel therapies in immuno-oncology and cell therapy.
Lead Product(s): NK cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 21, 2020